The Potential of AAV-Mediated Gene Targeting for Gene and Cell Therapy Applications

Current Stem Cell Reports

Volumn 1, Issue 1, 2015, Pages 16-22

  Alexander, Ian E ^a,b,e   Russell, David W ^c,d  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e CHILDREN'S MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

AAV mediated gene targeting; Genome editing; Homologous recombination

Indexed keywords

ADENO ASSOCIATED VIRUS; CELL THERAPY; DRUG RESEARCH; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; GENOMICS; HUMAN; IMMUNOBIOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS REPLICATION;

EID: 84991042923     PISSN: None     EISSN: 21987866     Source Type: Journal    
DOI: 10.1007/s40778-014-0001-1     Document Type: Review

References (71)

1. Segal DJ, Meckler JF. Genome engineering at the dawn of the golden age. Annu Rev Genomics Hum Genet. 2013;14:135–58.
2. Russell DW, Hirata RK. Human gene targeting by viral vectors. Nat Genet. 1998;18(4):325–30.
3. Hendrie PC, Russell DW. Gene targeting with viral vectors. Mol Ther. 2005;12(1):9–17.
4. Nirenberg MW. Will society be prepared? Science. 1967;157(3789):633.
5. Morecki S, Karson E, Cornetta K, Kasid A, Aebersold P, Blaese RM, et al. Retrovirus-mediated gene transfer into CD4+ and CD8+ human T cell subsets derived from tumor-infiltrating lymphocytes and peripheral blood mononuclear cells. Cancer Immunol Immunother. 1991;32(6):342–52.
6. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science. 1995;270(5235):475–80.
7. Roberts RJ. Restriction endonucleases. CRC Crit Rev Biochem. 1976;4(2):123–64.
8. Miller AD. Retroviral vectors. Curr Top Microbiol Immunol. 1992;158:1–24.
9. Miller AD. Human gene therapy comes of age. Nature. 1992;357(6378):455–60.
10. Folger KR, Wong EA, Wahl G, Capecchi MR. Patterns of integration of DNA microinjected into cultured mammalian cells: evidence for homologous recombination between injected plasmid DNA molecules. Mol Cell Biol. 1982;2(11):1372–87.
11. Smithies O, Gregg RG, Boggs SS, Koralewski MA, Kucherlapati RS. Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination. Nature. 1985;317(6034):230–4.
12. Capecchi MR. Altering the genome by homologous recombination. Science. 1989;244(4910):1288–92.
13. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981;292(5819):154–6.
14. Bradley A, Evans M, Kaufman MH, Robertson E. Formation of germ-line chimaeras from embryo-derived teratocarcinoma cell lines. Nature. 1984;309(5965):255–6.
15. Zijlstra M, Li E, Sajjadi F, Subramani S, Jaenisch R. Germ-line transmission of a disrupted beta 2-microglobulin gene produced by homologous recombination in embryonic stem cells. Nature. 1989;342(6248):435–8.
16. Thomas KR, Deng C, Capecchi MR. High-fidelity gene targeting in embryonic stem cells by using sequence replacement vectors. Mol Cell Biol. 1992;12(7):2919–23.
17. Capecchi MR. Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first century. Nat Rev Genet. 2005;6(6):507–12.
18. Hinnen A, Hicks JB, Fink GR. Transformation of yeast. Proc Natl Acad Sci U S A. 1978;75(4):1929–33.
19. Thomas KR, Capecchi MR. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell. 1987;51(3):503–12.
20. Thomas KR, Folger KR, Capecchi MR. High frequency targeting of genes to specific sites in the mammalian genome. Cell. 1986;44(3):419–28.
21. Wong EA, Capecchi MR. Homologous recombination between coinjected DNA sequences peaks in early to mid-S phase. Mol Cell Biol. 1987;7(6):2294–5.
22. Atchison RW, Casto BC, Hammon WM. Adenovirus-associated defective virus particles. Science. 1965;149:754–6.
23. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol. 1992;158:97–129.
24. Samulski RJ, Chang LS, Shenk T. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J Virol. 1987;61(10):3096–101.
25. Hermonat PL, Muzyczka N. Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci U S A. 1984;81(20):6466–70.
26. Tratschin JD, Miller IL, Smith MG, Carter BJ. Adeno-associated virus vector for high-frequency integration, expression, and rescue of genes in mammalian cells. Mol Cell Biol. 1985;5(11):3251–60.
27. Chao H, Liu Y, Rabinowitz J, Li C, Samulski RJ, Walsh EW. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther. 2000;2(6):619–23.
28. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol. 1998;72(3):2224–32.
29. Fisher KJ, Gao GP, Weitzman MD, DeMatteo R, Burda JF, Wilson JM. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol. 1996;70(1):520–32.
30. Thomas CE, Storm TA, Huang Z, Kay MA. Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol. 2004;78(6):3110–22.
31. Sanlioglu S, Monick MM, Luleci G, Hunninghake GW, Engelhardt JF. Rate limiting steps of AAV transduction and implications for human gene therapy. Curr Gene Ther. 2001;1(2):137–47.
32. Nonnenmacher M, Weber T. Intracellular transport of recombinant adeno-associated virus vectors. Gene Ther. 2012;19(6):649–58.
33. Kotterman MA, Schaffer DV. Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet. 2014;15(7):445–51.
34. Asokan A, Schaffer DV, Samulski RJ. The AAV vector toolkit: poised at the clinical crossroads. Mol Ther. 2012;20(4):699–708.
35. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther. 2006;14(3):316–27.
36. Ellis J, Bernstein A. Gene targeting with retroviral vectors: recombination by gene conversion into regions of nonhomology. Mol Cell Biol. 1989;9(4):1621–7.
37. Wang Q, Taylor MW. Correction of a deletion mutant by gene targeting with an adenovirus vector. Mol Cell Biol. 1993;13(2):918–27.
38. Russell DW, Miller AD, Alexander IE. Adeno-associated virus vectors preferentially transduce cells in S phase. Proc Natl Acad Sci U S A. 1994;91(19):8915–9.
39. Inoue N, Dong R, Hirata RK, Russell DW. Introduction of single base substitutions at homologous chromosomal sequences by adeno-associated virus vectors. Mol Ther. 2001;3(4):526–30.
40. Hirata R, Chamberlain J, Dong R, Russell DW. Targeted transgene insertion into human chromosomes by adeno-associated virus vectors. Nat Biotechnol. 2002;20(7):735–8.
41. Russell DW, Hirata RK. Human gene targeting favors insertions over deletions. Hum Gene Ther. 2008;19(9):907–14.
42. Hirata RK, Russell DW. Design and packaging of adeno-associated virus gene targeting vectors. J Virol. 2000;74(10):4612–20.
43. Miller DG, Petek LM, Russell DW. Human gene targeting by adeno-associated virus vectors is enhanced by DNA double-strand breaks. Mol Cell Biol. 2003;23(10):3550–7.
44. Cornea AM, Russell DW. Chromosomal position effects on AAV-mediated gene targeting. Nucleic Acids Res. 2010;38(11):3582–94.
45. Trobridge G, Hirata RK, Russell DW. Gene targeting by adeno-associated virus vectors is cell-cycle dependent. Hum Gene Ther. 2005;16(4):522–6.
46. Deyle DR, Hansen RS, Cornea AM, Li LB, Burt AA, Alexander IE, et al. A genome-wide map of adeno-associated virus-mediated human gene targeting. Nat Struct Mol Biol. 2014;21(11):969–75. This paper shows preferential AAV-mediated gene targeting in transcription units, particularly when the target locus is transcribed towards an incoming replication fork. Colliding polymerases therefore appear to exert a strong recombinogenic effect.
47. Deyle DR, Li LB, Ren G, Russell DW. The effects of polymorphisms on human gene targeting. Nucleic Acids Res. 2014;42(5):3119–24.
48. Khan IF, Hirata RK, Russell DW. AAV-mediated gene targeting methods for human cells. Nat Protoc. 2011;6(4):482–501.
49. Hendrie PC, Hirata RK, Russell DW. Chromosomal integration and homologous gene targeting by replication-incompetent vectors based on the autonomous parvovirus minute virus of mice. J Virol. 2003;77(24):13136–45.
50. Kan Y, Ruis B, Lin S, Hendrickson EA. The mechanism of gene targeting in human somatic cells. PLoS Genet. 2014;10(4):e1004251.
51. Humbert O, Davis L, Maizels N. Targeted gene therapies: tools, applications, optimization. Crit Rev Biochem Mol Biol. 2012;47(3):264–81.
52. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339(6121):819–23.
53. Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol. 2013;31(9):827–32.
54. Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE, et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell. 2013;154(6):1380–9.
55. Khan IF, Hirata RK, Wang P-R, Li Y, Kho J, Nelson A, et al. Engineering of human pluripotent stem cells by AAV-mediated gene targeting. Mol Ther. 2010;18(6):1192–9.
56. Riolobos L, Hirata RK, Turtle CJ, Wang PR, Gornalusse GG, Zavajlevski M, et al. HLA engineering of human pluripotent stem cells. Mol Ther. 2013;21(6):1232–41.
57. Deyle DR, Khan IF, Ren G, Wang PR, Kho J, Schwarze U, et al. Normal collagen and bone production by gene-targeted human osteogenesis imperfecta iPSCs. Mol Ther. 2012;20(1):204–13.
58. Chamberlain JR, Schwarze U, Wang PR, Hirata RK, Hankenson KD, Pace JM, et al. Gene targeting in stem cells from individuals with osteogenesis imperfecta. Science. 2004;303(5661):1198–201.
59. Chamberlain JR, Deyle DR, Schwarze U, Wang P, Hirata RK, Li Y, et al. Gene targeting of mutant COL1A2 alleles in mesenchymal stem cells from individuals with osteogenesis imperfecta. Mol Ther. 2008;16(1):187–93.
60. Hirata RK, Xu C, Dong R, Miller DG, Ferguson S, Russell DW. Efficient PRNP gene targeting in bovine fibroblasts by adeno-associated virus vectors. Cloning Stem Cells. 2004;6(1):31–6.
61. Walasek MA, van Os R, de Haan G. Hematopoietic stem cell expansion: challenges and opportunities. Ann N Y Acad Sci. 2012;1266:138–50.
62. Dane AP, Wowro SJ, Cunningham SC, Alexander IE. Comparison of gene transfer to the murine liver following intraperitoneal and intraportal delivery of hepatotropic AAV pseudo-serotypes. Gene Ther. 2013;20(4):460–4.
63. Alexander IE, Cunningham SC, Logan GJ, Christodoulou J. Potential of AAV vectors in the treatment of metabolic disease. Gene Ther. 2008;15(11):831–9.
64. Miller DG, Wang PR, Petek LM, Hirata RK, Sands MS, Russell DW. Gene targeting in vivo by adeno-associated virus vectors. Nature Biotechnol. 2006;24(8):1022–6.
65. Paulk NK, Wursthorn K, Wang Z, Finegold MJ, Kay MA, Grompe M. Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology. 2010;51(4):1200–8.
66. Li H, Haurigot V, Doyon Y, Li T, Wong SY, Bhagwat AS, et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature. 2011;475(7355):217–21.
67. Barzel A, Paulk NK, Shi Y, Huang Y, Chu K, Zhang F, et al. Promoterless gene targeting without nucleases ameliorates haemophilia B in mice. Nature. 2014. This is the first report of successful phenotype correction in vivo using AAV-mediated gene targeting without the need to first induce DNA strand breaks at the target locus. While markedly greater gene targeting efficiencies and/or selective expansion of corrected cells will be required for the majority of genetic diseases, this study is an exciting exemplar of the trajectory of the field.
68. Wang PR, Xu M, Toffanin S, Li Y, Llovet JM, Russell DW. Induction of hepatocellular carcinoma by in vivo gene targeting. Proc Natl Acad Sci U S A. 2012;109(28):11264–9.
69. Lisowski L, Dane AP, Chu K, Zhang Y, Cunningham SC, Wilson EM, et al. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature. 2014;506(7488):382–6.
70. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365(25):2357–65.
71. Logan GJ, de Alencastro G, Alexander IE, Yeoh G. Exploiting the unique regenerative capacity of the liver to underpin cell and gene therapy strategies for genetic and acquired liver disease. Int J Biochem Cell Biol. 2014;56:141–52.